• A 22-yr-old man with acute myelocytic leukemia received a bone marrow transplant from a genotypically HLA-identical female sibling after cyclophosphamide preparation. (notifylibrary.org)
  • At 34 mo after transplant, marrow relapse and chloroma were documented. (notifylibrary.org)
  • All metaphase cells and karyotypes from peripheral blood and marrow samples showed no evidence of host cells from 3 wk after transplant through the time of marrow relapse. (notifylibrary.org)
  • The patient received a second bone marrow transplant from the same donor after preparation with busulfan and cyclophosphamide and attained a complete remission with full hematologic engraftment. (notifylibrary.org)
  • Methods Center for International Blood and Marrow Transplant Research data from 184 adults who completed the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) before undergoing alloHCT and at day 100 were used. (cdc.gov)
  • Regret was measured using a FACT-BMT item not included in scoring: "I regret having the bone marrow transplant. (cdc.gov)
  • In a newly reported study, an experimental antibody treatment largely prevented gastrointestinal acute graft versus host disease (GI-aGVHD) in the intestines of mice and non-human primates (NHPs) given a bone marrow transplant-allogeneic hematopoietic cell transplant (allo-HCT)-but without causing broad immune suppression. (genengnews.com)
  • And even when a bone marrow transplant is curative for leukemia or lymphoma, GVHD-in which T cells in the donor graft attack the recipient's own tissues-can still be fatal. (genengnews.com)
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
  • Total marrow and lymphoid irradiation may allow a greater dose of radiation to be delivered to the bone marrow as a preparative regimen before hematopoietic cell transplant while causing less side effects to normal organs than standard total body irradiation. (survivornet.com)
  • TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0. (survivornet.com)
  • Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). (einpresswire.com)
  • People with life-threatening cancers, such as leukemia , lymphoma , and myeloma can be treated with a bone marrow transplant or, sometimes, a stem cell transplant. (medlineplus.gov)
  • Autologous bone marrow transplant is when people donate their own bone marrow. (medlineplus.gov)
  • Allogenic bone marrow transplant is when another person donates bone marrow. (medlineplus.gov)
  • But only about 30% of people who need a bone marrow transplant can find a matching donor in their own family. (medlineplus.gov)
  • Doctors can then use the registry to find a matching donor for a person who needs a bone marrow transplant. (medlineplus.gov)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • Blood Marrow Transplant. (bcm.edu)
  • Ramos CA " Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia. . (bcm.edu)
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • Data of 58 113 HSCTs (allogeneic: 63% vs autologous: 37%) performed between 1986 and 2006 by 432 transplant teams were collected. (nus.edu.sg)
  • Apamistamab (Iomab-B) conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia (AML), according to interim results from the phase 3 SIERRA trial, which were presented virtually at the 2021 Transplant and Cellular Therapies Meetings. (onclive.com)
  • In these patients with relapsed or refractory AML, we observed high rates of allogeneic stem cell transplant with curative intent [in] 88% of patients on the Iomab-B arm, 18% of patients who were randomized to the conventional care arm achieved complete remission and received standard of care allo-transplant, and an overall rate of 79% of allo-transplant in all enrolled patients," Boglarka Gyurkocza, MD, said in a virtual presentation. (onclive.com)
  • Forty-eight percent of patients (29/61) were heavily pretreated, defined as having at least one of the following: prior radiation, greater than or equal to 3 prior chemotherapeutic regimens, or prior hematopoietic stem cell transplant. (clustermed.info)
  • Incidence varies among studies, but is reportedly 0-11.6% after bone marrow or PBSC transplantation and 4.9-21.4% after umbilical cord blood transplantation, typically around 2-6 weeks post transplant. (qxmd.com)
  • Forty cases were identified, of which 29 (72.5%) received hematopoietic stem cell transplant (HSCT)-related therapy. (bvsalud.org)
  • This retrospective study was conducted at a Japanese center specializing in hematopoietic stem cell transplants and found that the rare pathogen Candida guilliermondii complex was the most common cause of breakthrough candidemia, with high mortality rate, which is a concern for transplant patients. (bvsalud.org)
  • Cytomegalovirus glycoprotein B and N genotypes in pediatric recipients of the hematopoietic stem cell transplant. (cdc.gov)
  • 0103 Genotype in Survival of Patients After Allogeneic Hematopoietic Stem Cell Transplant. (cdc.gov)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (nature.com)
  • Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. (nature.com)
  • Currently, my work aims to establish strategies to reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease or interfering with donor stem cell engraftment. (stanford.edu)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • Therapeutic Candidate or Device OSSM007: cryopreserved, interferon-gamma-primed bone marrow mesenchymal stem cells (BM-MSC) Indication acute Graft versus host disease (aGVHD) resulting from hematopoietic cell transplantation Therapeutic Mechanism Immunomodulation of host-reactive T cells to induce operational tolerance of donor HSC-derived lymphocytes through direct cell-to-cell contact and secreted paracrine factors. (ca.gov)
  • Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's tissues). (survivornet.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • The year 2020 marked the 30th anniversary of the Nobel Prize in Medicine awarded to E. Donnall Thomas for the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat hematologic malignancies and other blood disorders. (broadinstitute.org)
  • Relapsed or refractory was defined as relapsed with first remission duration of less than 12 months in the first salvage, or relapsed or refractory after first salvage therapy, or relapsed within 12 months of allogeneic hematopoietic stem cell transplantation (HSCT), and had greater than 10 percent blasts in bone marrow. (southcarolinablues.com)
  • Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. (biomedcentral.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure, and is usually conducted to consolidate remission of haematological malignancies. (biomedcentral.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • The hematopoietic SCT (HSCT) activity in nine Asian countries/regions was surveyed to overview the current situation. (nus.edu.sg)
  • Autoimmune hemolytic anemia (AIHA) after allogeneic hematopoietic stem cell transplantation (HSCT) is still not well characterized. (elsevierpure.com)
  • The aim of this study was to analyze the incidence and risk factors for the development of AIHA, as well as its prognosis and response to treatment in a series of patients undergoing allogeneic HSCT at a single institution. (elsevierpure.com)
  • Between 1996 and 2004, 272 adult patients with a variety of malignant hematopoietic disorders underwent allogeneic HSCT. (elsevierpure.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR T-cell therapy has emerged as a promising strategy to prolong LFS. (biomedcentral.com)
  • For decades, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been regarded as the only well-established curative cellular therapy for patients with B-ALL. (biomedcentral.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. (oncotarget.com)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • The condition is among the leading causes of death and long-term adverse health consequences associated with bone marrow transplants. (genengnews.com)
  • A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs) can reestablish the health-promoting bacteria that are often damaged by intense antibiotic treatment in people who have stem cell or bone marrow transplants for blood cancer. (mskcc.org)
  • Bone marrow transplants work best if the HLAs from the donor and the patient are a close match. (medlineplus.gov)
  • February 11, 2021 - Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia. (onclive.com)
  • Each year, more than 50,000 allogeneic transplants are performed worldwide. (cdc.gov)
  • The number of human tissue transplants is increasing in both developed and developing countries, but global data on this form of transplantation are less complete. (who.int)
  • Access to transplantation is limited in low- and many medium-income countries, where the rate of transplants remains far below that of richer nations. (who.int)
  • Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. (nih.gov)
  • Full hematopoietic engraftment was reported in one case after bone marrow transplantation without conditioning for a SCID patient. (nih.gov)
  • Chimerism analysis - testing of short tandem repeat regions to assess donor bone marrow engraftment. (ouh.nhs.uk)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • V. Cellular and molecular assessment of TMLI effect on bone marrow environment and TMLI effect on the engraftment and disease relapse. (survivornet.com)
  • Kamble RT, Guo S, Ramos CA, Carrum G " Acute gout at engraftment following hematopoietic transplantation. . (bcm.edu)
  • Investigators sought to prove with this study that targeted radiation to the marrow with apamistamab, a radioactive iodine ( 131 I)-labeled anti-CD45 antibody, could enable the successful engraftment of patients despite active disease in the marrow. (onclive.com)
  • The three sources of stem cells include bone marrow, umbilical cord blood, and peripheral blood. (oncologynurseadvisor.com)
  • Patients are eligible for enrollment if they have marrow blast count ≥ 5% or the presence of peripheral blasts, age ≥ 55 years, a Karnofsky score ≥ 70, and related/unrelated donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1. (onclive.com)
  • Workup may include a complete blood count (CBC), peripheral smear, iron studies (eg, ferritin and total iron-binding capacity [TIBC]), bone marrow aspiration and biopsy, and other studies as appropriate. (medscape.com)
  • Examination of peripheral blood smear and bone marrow is diagnostic. (msdmanuals.com)
  • 1 This includes human cells for transplantation such as haematopoietic stem cells from bone marrow, peripheral blood or cord blood. (who.int)
  • Data from autosomal and sex chromosome studies indicate that the marrow relapse occurred in cells of donor origin. (notifylibrary.org)
  • however, nearly all cases eventually relapse, and allogeneic stem cell transplantation remains the only curative treatment option for a small subset of patients. (haematologica.org)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • Treatment includes induction chemotherapy to achieve remission and postremission chemotherapy (with or without stem cell transplantation) to avoid relapse. (msdmanuals.com)
  • Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of reticulin and collagen fibrosis in the bone marrow of patients with myelofibrosis is believed to be mediated by the myelofibrosis hematopoietic stem/progenitor cell, contributing to an impaired microenvironment favoring malignant over normal hematopoiesis. (haematologica.org)
  • This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. (survivornet.com)
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? (biomedcentral.com)
  • In acute myeloid leukemia (AML), malignant transformation and uncontrolled proliferation of an abnormally differentiated, long-lived myeloid progenitor cell results in high circulating numbers of immature blood cells and replacement of normal marrow by malignant cells. (msdmanuals.com)
  • Aplastic anemia due to the progressive failure of the bone marrow, malignant neoplasias such as acute myeloid leukemia, liver tumors and squamous cell carcinoma are some of the possible evolutions of Fanconi Anemia. (bvsalud.org)
  • Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. (nature.com)
  • The median time for onset of stage 3-4 gut GVHD was 35 (4-135) days after allogeneic HCT. (nature.com)
  • In experiments with mouse models of GVHD, the researchers showed that blocking a particular Notch activator known as DLL4 effectively prevented GVHD when administered within the first days after transplantation. (genengnews.com)
  • The team confirmed that the Notch pathway involvement in GVHD was conserved across species, and demonstrated in their animal models that just a single dose of the DLL4-blocking antibody given immediately before stem cell transplantation greatly increased survival and prevented signs of GVHD in the intestines, but without causing global immunosuppression. (genengnews.com)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
  • In the field of hematopoietic stem cell transplantation, Maloney has played a role in the development of lower-toxicity, non-myeloablative techniques for the treatment of blood cancers. (wikipedia.org)
  • Chemotherapy, either at conventional levels or in the higher-dosed myeloablative protocols used in conditioning regimens (with or without total body radiation in preparation for hematopoietic cell transplantation [HCT]), often results in erythema, edema, atrophy, and ulceration of the oral mucosa, a condition generally referred to as oral mucositis. (medscape.com)
  • Reduced mortality after allogeneic hematopoietic-cell transplantation. (nature.com)
  • Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. (aamds.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • Background: Allogeneic hematopoietic stem cell transplantation (alloHCT) is potentially curative but with known negative effects on quality of life. (cdc.gov)
  • Allogeneic hematopoietic cell transplantation (allo-HCT) has lifesaving potential for patients with hematological malignancies and bone marrow disorders, the authors wrote. (genengnews.com)
  • The 10-years EBMT Landscape of Allogeneic Hematopoietic Cell Transplantation (Allohct) for Chronic Lymphocytic Leukemia. (uni-koeln.de)
  • Perception of Late Effects among Long-Term Survivors after Hematopoietic Stem Cell Transplantation: Descriptive Analysis and Validation of the Brief Illness Perception Questionnaire. (zhaw.ch)
  • 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. (broadinstitute.org)
  • Dr. Thomas, "father of bone marrow transplantation," first developed and reported this technique in 1957, and in the ensuing decades, this seminal study has impacted fundamental work in hematology and cancer research, including advances in hematopoiesis, stem cell biology, tumor immunology, and T-cell biology. (broadinstitute.org)
  • Hematopoietic stem cell transplantation remains the only curative therapeutic approach that reliably results in resolution of bone marrow fibrosis in patients with myelofibrosis. (haematologica.org)
  • We discuss the rationale of various anti-fibrogenic treatment strategies targeting the clonal hematopoietic stem/progenitor cell, aberrant signaling pathways, fibrogenic cytokines, and the tumor microenvironment. (haematologica.org)
  • 3 Myelofibrosis (MF) refers to the Philadelphia chromosome ( BCR-ABL1 )-negative myeloproliferative neoplasm (MPN) originating at the level of the multipotent hematopoietic stem cell. (haematologica.org)
  • Bio My research is focused on using preclinical models to develop novel therapies which improve outcomes for patients receiving allogeneic hematopoietic stem cell transplantation. (stanford.edu)
  • Journal of Stem Cell Research and Transplantation is an international, open access, peer reviewed, scholarly journal committed to publish articles in diversified fields of transplantations and applications of stem cell research. (slideshare.net)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • The Journal of Stem Cell Research and Transplantation publishes latest scientific information, and is generously accessible across the world through internet to go halves the innovations of the researchers for intellectual advancement in this field. (slideshare.net)
  • 184 had no cardiac events after stem cell transplantation. (slideshare.net)
  • Discussion Stem cell transplantation is well and truly underway in South East Asia. (slideshare.net)
  • In allogeneic hematopoietic cell transplantation (allo-HCT), a person's stem cells are replaced with healthy new stem cells. (mskcc.org)
  • Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. (einpresswire.com)
  • Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? (biomedcentral.com)
  • Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B " Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. . (bcm.edu)
  • Pharmacokinetics The pharmacokinetics of BUSULFEX were studied in 59 patients participating in a prospective trial of a BUSULFEX-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. (clustermed.info)
  • Prospective Clinical Trial of BUSULFEX: The prospective trial was a single-arm, open-label study in 61 patients who received BUSULFEX as part of a conditioning regimen for allogeneic hematopoietic stem cell transplantation. (clustermed.info)
  • Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. (uchicago.edu)
  • Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? (ashpublications.org)
  • 1-3 This has downscaled the role of allogeneic hematopoietic cell transplantation (allo-HCT) as the formerly most effective treatment of HR-CLL. (ashpublications.org)
  • 2006). Heath-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. (bvsalud.org)
  • Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. (qxmd.com)
  • Human herpesvirus-6 (HHV-6) encephalitis following allogeneic hematopoietic cell transplantation is a serious and often fatal complication accompanying reactivation of HHV-6B. (qxmd.com)
  • The deduced probable HLA-C*03:187-associated human leukocyte antigen haplotype (A*24:02-B*35:01-C*03:187-DRB1*11:01) revealed in Taiwanese unrelated hematopoietic bone marrow stem cell donors. (cdc.gov)
  • and hematopoietic stem cell safety. (cdc.gov)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • To the best of our knowledge, only the transmission of malarial parasites has been reported during stem cell transplantation. (cdc.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Organ Transplantation.2 These Guiding Principles - whose emphases include voluntary donation, noncommercialization, genetic relation of recipients to donors and a preference for cadavers over living donors as sources - have considerably influenced professional codes, national, state and provincial legislation, and the policies of intergovernmental organizations. (who.int)
  • In the study, patients with active, relapsed, refractory AML are randomized 1:1 to receive either apamistamab conditioning therapy and allogeneic HCT or conventional care. (onclive.com)
  • [ 12 ] is a juvenile multisystem disorder caused by deletions in mitochondrial DNA (mtDNA) and manifested as severe, refractory sideroblastic anemia, neutropenia, vacuolated cells in bone-marrow precursors, exocrine pancreas insufficiency, malabsorption, and growth failure. (medscape.com)
  • Seven eighty six patients undergoing allogeneic (n=550) or autologous (n=236) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 5 months thereafter. (slideshare.net)
  • The specific effect on bone marrow fibrosis of JAK2 inhibition, and other rationally based therapies currently being evaluated in myelofibrosis, has yet to be fully elucidated. (haematologica.org)
  • Longitudinal and spatial assessment of TMLI effect on bone marrow environment. (survivornet.com)
  • The 5-year probabilities of overall survival adjusted for interval from diagnosis to transplantation, and performance score was 58% for African Americans and 73% for Caucasians. (aamds.org)
  • For example, in developing and developed countries alike, kidney transplantation not only yields survival rates and quality-of-life that are far superior to those obtained with other treatments for end-stage renal disease, such as haemodialysis, but is also less costly in the long run. (who.int)
  • Access to transplantation entails more than the surgery itself, because success is measured by longer survival of the patient and a long-term improvement in the quality of life. (who.int)
  • Because the chromosomal t(14;18) translocation is found in the majority of patients with follicular lymphoma, bone marrow aspiration and chromosome analysis can also help establish the diagnosis. (medscape.com)
  • Bone marrow aspiration is performed after hematopoietic recovery, or day 28 at the latest. (cancercentrum.se)
  • However, modern myelofibrosis prognostication systems utilized in risk-adapted treatment approaches do not include bone marrow fibrosis as a prognostic variable. (haematologica.org)
  • Most patients with follicular lymphoma present at an advanced stage, and most patients have bone marrow involvement at diagnosis. (medscape.com)
  • Sideroblastic anemia is primarily a laboratory diagnosis, made on the basis of bone-marrow examination with Prussian blue stain. (medscape.com)
  • Of these, 27.91% had a main diagnosis indicating the transplantation of Multiple Myeloma (MM), and 58.14 received autologous transplantation. (bvsalud.org)
  • In all patients that might become considered for intensive treatment, the AML diagnosis should be based on morphologic and immunophenotypic features of bone marrow aspirates as well as on genetic characteristics of the leukemic blasts. (cancercentrum.se)
  • Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. (einpresswire.com)
  • Conclusions: Among patients who underwent alloHCT and lived to 100 days, the majority did not report regretting their transplantation. (cdc.gov)
  • Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits lost owing to the disease Unmet Medical Need There are currently disease modifying therapies. (ca.gov)
  • Therapeutic Candidate or Device Autologous hematopoietic stem cells transduced with a HexA/HexB expressing lentiviral vector Indication Tay-Sachs disease Therapeutic Mechanism The transplanted gene modified autologous hematopoietic stem cells will engraft in the bone marrow and start producing HexA/HexB expressing immune progeny. (ca.gov)
  • Therapeutic Candidate or Device Hematopoietic stem and progenitor cells collected from X-CGD patients modified with a highly regulated lentiviral vector Indication X-linked Chronic Granulomatous Disease Therapeutic Mechanism Lentiviral vector (LV) modification of autologous hematopoietic stem and progenitor cells (HSPCs) to restore physiologic gp91phox expression. (ca.gov)
  • In the SIERRA trial, patient-specific dosimetry was used to generate an individualized therapeutic dose to target marrow and spare non-hematopoietic organs. (onclive.com)
  • However, better understanding of the role of increased JAK-STAT signaling [either through activating mutations ( JAK2 , MPL515L/K ) within the signaling pathway, or mutations involving CALR ], the role of deregulated pro-inflammatory cytokine expression, and the impaired bone marrow microenvironment is transforming the treatment approach for MF. (haematologica.org)
  • For this type of treatment, bone marrow is collected from a donor. (medlineplus.gov)
  • EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (biomedcentral.com)
  • percent of marrow blasts at baseline was 29% (range, 4%-95%), and had received a median of 3 prior treatment regimens (range, 1-7). (onclive.com)
  • Moreover, for patients who have kidney failure, access to transplantation is reduced when funds are spent on other forms of treatment that are less cost-effective. (who.int)
  • Bone marrow transplantation is the only treatment of SCID. (lu.se)
  • Total body irradiation is a form of radiotherapy that involves irradiating the patient's entire body in an attempt to suppress the immune system, prevent rejection of the transplanted bone marrow and/or stem cells and to wipe out any remaining cancer cells. (survivornet.com)
  • 8. Subjects are allowed to receive palliative radiation therapy (including brain radiotherapy for symptomatic brain metastases and radiotherapy for bone metastases), but the radiotherapy must be completed at least 1 week before enrollment, and the toxicity related to radiotherapy should be restored to less than or equal to 1 degree (CTCAE 5.0, excluding hair loss). (who.int)
  • Sideroblasts are not pathognomonic of any one disease but rather are a bone marrow manifestation of several diverse disorders. (medscape.com)
  • The increase in allogeneic HSCTs is greater than in autologous HSCTs. (nus.edu.sg)
  • 6 Causes of early death include leukemic transformation, complications arising from progressive bone marrow failure, portal/pulmonary hypertension, infections, thrombosis and bleeding. (haematologica.org)
  • Transplantation of human organs and tissues1 saves many lives and restores essential functions in circumstances when no medical alternative of comparable effectiveness exists. (who.int)
  • The transplantation of solid organs, such as kidney, liver, heart or lung, is increasingly a regular component of health care in all countries, and is no longer a feature of health care in high-income countries alone. (who.int)
  • Nonetheless, the transplantation of organs and tissues does raise ethical concerns. (who.int)
  • The persistent and widening gap between patients' need for organs and the number available for transplantation has become a major concern to many Member States. (who.int)
  • Successful transplantation of organs and living tissues depends on continued medical follow-up and the patient's compliance with a regimen of immunosuppressive drugs. (who.int)
  • The risk of regretting transplantation was 17.5 percentage points (95% confidence interval, 5.5-29.7 percentage points) greater in patients who developed disease recurrence after HCT compared with patients who did not. (cdc.gov)
  • Symptoms related to bone marrow dysfunction, such as anemia, leukopenia, or thrombocytopenia, are rare at presentation but can also be observed in the later stages of the disease. (medscape.com)
  • I. Characterize minimal residual disease from bone marrow aspirates and investigate the possible association between TMLI-based regimen and patient's disease status. (survivornet.com)
  • A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. (haematologica.org)
  • In the conventional care arm, the median age was 65 years (range, 55-77), 32% had intermediate risk and 63% had adverse risk, median marrow blasts was 20% (range, 5%-97%), and had received a median of 3 prior regimens (range, 1-6). (onclive.com)
  • The primary endpoint will assess the effect of EN on D100 mortality. (biomedcentral.com)